CibusCBUS
Recorded

Cibus 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration48 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please stand by. Your meeting is about to begin. Good afternoon, and welcome to the Cibus Third Quarter 2026 Results Conference Call. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. Please also note today's event is being recorded. At this time, I would like to turn the conference call over to Carlo Broos, Chief Financial Officer. Sir, please go ahead. Thank you, and good afternoon.

Carlo BroosCFO

I would like to thank you for taking the time to join us for Cibus Third Quarter 2026 Financial Results and Business Update Conference Call and Webcast. Presenting with me today is Craig Wichner, our Chief Executive Officer, and Peter Beetham, Co-Founder, President, and Chief Operating Officer. Greg Gocal, Chief Scientific Officer, is available to participate during the Q&A portion of the call. Before we begin the call, I would like to remind everyone that statements made on the call and the webcast, including those regarding future financial results and future operational goals and industry prospects, are forward-looking and may be subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the call. Please refer to Cibus SEC filings for a list of associated risks. This conference call is being webcast.

Carlo BroosCFO

The webcast link, along with our press release and corporate presentation, are available on the Investor Relations section of cibus.com to assist you in your analysis of our business. With that, I would like to turn the call now over to Craig.

Craig WichnerCEO

Thank you, Carlo, and good afternoon, everyone. Three months ago, on my first call as CEO, I described three ways our Cibus platform technology creates value: platform programs that generate revenue today, royalties as our traits reach acres, and partnerships that deepen over time. Today, I will briefly report against those three and share a bit on why each one is important. I also want to spend a few minutes on what makes our Direct Breeding platform faster than the other two most common forms of improving a seed. The first tier of our business is platform programs. Let me start with bio-fragrances. We have initiated manufacturing process for anticipated production runs of our first bio-fragrances, and our partner has asked for larger quantities of two more to advance its product development.

Craig WichnerCEO

The reason this program exists is that consumer products companies want fragrance ingredients made in a more sustainable way. Ours are grown with proprietary yeast and extracted after fermentation, rather than made from petroleum or harvested at scale from fields of flowers. It is the same platform applied to a microbe instead of a crop, and it's the first place where something we designed is being prepared for scale-up towards commercial production. The second program is new. In September, we announced a partner-funded program with Crystal Crop to develop traits for mustard in India, and the work began in the quarter. Why mustard and why India? India grows more mustard than any other country. Mustard is almost a third of its oilseed production, and India imports more than half of the edible oil it consumes.

Craig WichnerCEO

Indian mustard yields run roughly a third below the leading producing countries, and breeders have struggled for decades to close that gap. Disease and weeds can take a third of the yield, and India's growers have none of the herbicide-tolerant or disease-resistant varieties that competing producers rely on. Those are the kinds of traits we make, and our platform can make several edits at once in a partner's own varieties. India's government has made this a national mission, with a target of nearly doubling the country's oilseed harvest by 2030 and 2031, and it names genome editing among the tools that we'll use to get there. We believe India's rules for edits with no foreign DNA support a path to the field, and Crystal Crop will evaluate the traits in India.

Craig WichnerCEO

A better mustard crop could mean more income for the growers and more of India's cooking oil grown at home. The third program is in the U.K., where we are developing resistance to a disease called light leaf spot in oilseed rape, which is similar to canola. Light leaf spot is one of the most damaging diseases of Britain's oilseed rape crop, and it cost British growers an estimated GBP 300 million in 2022, an unusually severe year, and the fungicides that used to control it are losing their efficacy. A consortium of farmers, breeders, and research institutes, funded in part through the Farming Innovation Program of DEFRA, the U.K.'s Environment and Farming Department, chose Cibus to make the edits in elite winter oilseed rape, and that work is on schedule.

Craig WichnerCEO

Both crop programs are funded by others, a government-supported consortium and a seed company paying Cibus to put a trait into their plants. The second tier is trait royalties, led by rice. For farmers, weeds cost yield and quality. In rice, the hardest to control are grass weeds, and the worst of them is weedy rice, which is almost genetically identical to a rice plant, so that anything that kills it also kills the rice. Conventional herbicides have never had a good answer for it. We developed our rice traits so that a farmer can control these weeds without harming the rice. This quarter, we reported the first results from our trial in the rice varieties grown in Latin America, and they were positive on trait performance. Interoc has now begun testing our traits in its own varieties in Ecuador, with results due in the first quarter of 2027.

Craig WichnerCEO

We continue to advance towards a definitive commercialization agreement with Interoc. Once commercialized, royalty revenue will be tied to the acres planted with seeds carrying our traits, and we expect rice to be the first crop where that model applies. Peter has the trials and the launch timing. The third tier is deepening partnerships. A quarter ago, we announced that Interoc widened its letter of intent from two traits to five. This quarter, it is the John Innes Centre, a leading plant science institute in the U.K. in 2022, it brought us its nutrient use efficiency discovery to edit into oilseed rape and rice. The light leaf spot gene target we are editing into oilseed rape came from the same institute and its partners at the University of Hertfordshire. Two discoveries, two programs with us, and we are exploring more with them.

Craig WichnerCEO

A partner that comes to us for one trait and asks for the next is where we believe this platform's economics can build. We expect that traits after the first can be faster and cheaper for us and the partners, and that one trait has the potential to go to multiple partners, crops, and geographies. Over time, the relationship can turn from a project into a pipeline. Let me spend some time on what makes our Direct Breeding platform different. Every crop in the world is the product of plant breeding, and breeding has always been indirect. To add a trait, a breeder crosses its best variety with a donor plant that carries the trait. The offspring is only half the variety the breeder wanted, and so it is crossed back round after round until the parent's variety's genetics are fully recovered with the trait included.

Craig WichnerCEO

That takes most of a decade in development and testing before years of growing enough seed to sell. The first generation of gene editing technology shortened the search for the right change, but most commonly, its editing machinery was introduced into the plant's DNA, so the machinery had to be bred out again through those same rounds. If several changes were made at different places in the genome, some of those were lost while the machinery was being bred out. Every one of those routes spends its years growing whole plants season after season. Cibus takes a different approach. We take a single cell from the seed company's own best variety. We make the changes in that cell, several edits at once if the customers want them, and with editing tools that do their work and then break down.

Craig WichnerCEO

None of our editing tools are inserted into the plant's DNA, so our customers have nothing to breed out afterwards. We confirm the changes while they are still cells in a Petri dish. The edited cells grow into small clumps, and from those, we grow back whole edited plants. The variety that comes out is the variety that went in, now carrying the new traits, and it goes back to the seed company for its own testing and commercial development. We call this Direct Breeding. I want to highlight two very important outcomes that differentiate Direct Breeding from the ways of the past, because they are why I believe this platform has the potential to generate revenue at scale. The first is speed. In canola, we are able to return a customer's germplasm with trait edits within 12 to 15 months, and our goal is to achieve that similar turnaround of edits in other crops.

Craig WichnerCEO

The second is several edits at once. When inserted editing machinery has to be bred out, every extra edit multiplies the cleanup. Our platform leaves no machinery, just highly targeted edits, so a customer can ask for several edits at once. We do all of this inside our own partner's elite varieties. Unlike some larger companies, we sell no seeds and no chemicals, so we do not compete with our customers for seed sales, and seed companies of any size can work with us. Let me turn to our resources and how that informs our near-term strategy.

Craig WichnerCEO

We are scaling up our near-term revenue streams, but have financial constraints that we aim to overcome in the interim, which is keeping our team tightly focused on outcomes. In my first 100 days, we reviewed every program, every expense, every opportunity with the lens I described in August. What drives near-term revenue? What strengthens the balance sheet? What unlocks value in what we have already built? The review confirmed our focus on the two programs closest to revenue, Sustainable Ingredients and rice. It confirmed that we keep targeted investments in the programs we believe can create significant long-term value, nutrient use efficiency and disease resistance among them. We will limit incremental growth investment to our highest priority opportunities, and we will manage it inside the cash usage objectives we have given you.

Craig WichnerCEO

In short, we are more focused than ever on accelerating our priority programs within the same spending envelope. Carlo will give you the numbers and tell you how we are thinking about the balance sheet. With that, let me hand it to Peter. Peter? Thanks, Craig, and good afternoon, everyone.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day